Regulatory T cells (T regs ) are a barrier to anti-tumor immunity. Neuropilin-1 (Nrp1) is required to maintain intratumoral T reg stability and function but is dispensable for peripheral immune tolerance. T reg -restricted Nrp1 deletion results in profound tumor resistance due to T reg functional fragility. Thus, identifying the basis for Nrp1 dependency and the key drivers of T reg fragility could help to improve immunotherapy for human cancer. We show that a high percentage of intratumoral NRP1 + T regs correlates with poor prognosis in melanoma and head and neck squamous cell carcinoma. Using a mouse model of melanoma where Nrp1-deficient (Nrp1 -/-) and wild-type (Nrp1 +/+ ) T regs can be assessed in a competitive environment, we find that a high proportion of intratumoral Nrp1 -/-T regs produce interferon-g (IFNg), which drives the fragility of surrounding wild-type T regs , boosts anti-tumor immunity, and facilitates tumor clearance. We also show that IFNg-induced T reg fragility is required for response to anti-PD1, suggesting that cancer therapies promoting T reg fragility may be efficacious.
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Driving T reg fragility in the tumor microenvironment is critical for the efficacy of cancer checkpoint blockade therapy.
INTRODUCTION

Regulatory T cells (T regs )
, characterized by their expression of the forkhead box transcription factor, Foxp3, are required to maintain immune homeostasis and prevent excessive tissue damage (Fontenot et al., 2005; Kim et al., 2007; Miyara and Sakaguchi, 2007; Vignali et al., 2008) . Humans that lack a functional T reg population develop a lethal autoimmune disorder, termed immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome, which can be recapitulated in mice through Foxp3 deletion. While T regs are required to limit autoimmunity and maintain immune regulation, they can be deleterious in cancer through suppression of anti-tumor immunity (Chaudhry and Rudensky, 2013; Facciabene et al., 2012; Liu et al., 2016) . Indeed, high numbers of T regs and a low CD8 + T cell:T reg ratio are considered poor prognostic factors for many tumor types, including melanoma, head and neck squamous cell carcinoma (HNSCC), ovarian cancer, and colorectal carcinoma (Curiel et al., 2004; Drennan et al., 2013; Jacobs et al., 2012; Nishikawa and Sakaguchi, 2010; Saito et al., 2016) . Although targeting intratumoral T regs could be an effective therapeutic approach for multiple tumor types, perturbation of peripheral T reg number or function could lead to life-threatening autoimmune or inflammatory complications. Therefore, identifying pathways that could be targeted to selectively undermine intratumoral T regs is essential.
We have previously shown that Neuropilin-1 (Nrp1) is expressed by $90% of tumor infiltrating T regs in mouse models of cancer and is critical for their function in the tumor microenvironment (Delgoffe et al., 2013) . Indeed, mice with a T reg -restricted deletion of Nrp1 are highly resistant to B16 melanoma, which is normally refractory to immune-mediated clearance, yet remarkably do not exhibit any autoimmune or inflammatory disease. Although we have previously described Nrp1-deficient T regs as ''unstable,'' due to their loss of function (Delgoffe et al., 2013) , previous studies and data included here clearly show that they retain Foxp3 expression. Thus, we now refer to this phenotype as T reg ''fragility'' consistent with their retention of Foxp3 expression yet loss of function ex vivo (as exhibited by loss of suppressive activity in vitro) and tumor tolerance in vivo (as exhibited by tumor growth reduction/clearance). While our previous data demonstrated the importance of Nrp1 in maintaining intratumoral T reg function, many questions remain including the fate of these fragile T regs and their contribution to anti-tumor immunity, the drivers of T reg fragility, the expression, contribution, and impact of NRP1 on human intratumoral T regs , and the broader implications for T reg function and cancer immunotherapy.
RESULTS
Increased NRP1 Expression on T regs in Human Cancer
While Nrp1 has been shown to prevent T reg fragility in mice, its presence and role in human T regs remains unclear. Previous studies have been controversial, with some suggesting peripheral human T regs do not express NRP1 while others suggest that NRP1 + T regs are potent suppressors (Battaglia et al., 2008 (Battaglia et al., , 2009 Chaudhary and Elkord, 2015; Chaudhary et al., 2014; Gao et al., 2016; Milpied et al., 2009; Piechnik et al., 2013; Tatura et al., 2015) . Indeed, very few human T regs in peripheral blood lymphocytes (PBL) from healthy donors express NRP1 (Figures 1A and 1B) . Remarkably, most patients with metastatic melanoma and head and neck squamous cell carcinoma (HNSCC) possessed a reasonably high percentage of intratumoral NRP1 + T regs (Figures 1A and 1B) . This varied considerably from 3%-90% in melanoma and 35%-90% in HNSCC. The percentage of NRP1 + T regs in PBL was also substantially enhanced.
Interestingly, NRP1 expression in intratumoral T regs appeared to correlated with poor prognosis in both melanoma and HNSCC ( Figure 1C ).
Nrp1 -/-T regs Block WT T reg Function and Promote Anti-tumor Immunity
We have previously shown that anti-Nrp1 substantially limits the growth of a B16 mouse model of human melanoma (Delgoffe et al., 2013) . Given the heterogeneous nature of NRP1 expression on human tumor infiltrating T regs , where only a proportion express NRP1, we questioned what impact Nrp1 loss on only a proportion of mouse T regs might have on the function of the remaining wild-type (WT) counterparts and, by extension, anti-tumor immunity and tumor growth. Also, as Nrp1-deficient T regs show a reduction in suppressive function but also an increase in effector phenotype (Delgoffe et al., 2013) , we questioned whether these cells had an active role in re-shaping the tumor microenvironment, or whether reduced tumor growth was instead due to reduction of a major suppressive cell population.
Foxp3 is on the X chromosome and is thus subject to X inactivation (Briggs and Reijo Pera, 2014; Galupa and Heard, 2015; Lee and Bartolomei, 2013) (Delgoffe et al., 2013) . This occurred despite the presence of Nrp1 +/+ T regs in similar numbers to Nrp1 -/-T regs in the tumor ( Figure S1A ). A previous study suggested that the absence of Nrp1 leads to reduced influx of T regs into certain tumor types (Hansen et al., 2012) . However, there did not seem to be a significant difference in the number of intratumoral Nrp1 -/-versus
Cre-YFP/DTR-GFP mice (Figure S1A (Overacre and Vignali, 2016; Zhou et al., 2009b) . Indeed, we have previously shown that Nrp1 contributes to T reg stability in the tumor microenvironment by undermining the pAKT:FOXO pathway and preventing the expression of T helper lineage-defining transcription factors, raising the possibility that this may also result in the loss of Foxp3 expression. We analyzed Foxp3 fate-mapping mice in which T regs either possessed (Foxp3 Figures S2B and S2C ). These data suggest that the absence of Nrp1 does not affect Foxp3 expression and does not result in the generation of ex-T regs .
Previous reports have shown that T regs can display alternative functions in vivo while maintaining Foxp3 expression (Hori, 2014; Sharma et al., 2013 
Cre-YFP/DTR-GFP heterozygous and control mice using a microsuppression assay (Turnis et al., 2016) . While all T reg populations isolated from non-draining lymph nodes (ndLN) were equally capable of suppressing effector T cells ( Figure 1H 
Foxp3
Cre-YFP/DTR-GFP tumors lacked suppressive activity ( Figure 1H ). Interestingly, intratumoral Nrp1
Cre-YFP/DTR-GFP mice were also unable to suppress. Two hallmarks of T reg fragility are elevated pAkt and reduced ICOS expression (Delgoffe et al., 2013) . Elevated pAkt and reduced ICOS were observed in Nrp1
Cre-YFP/DTR-GFP (D-G) Foxp3
DTR-GFP/DTR-GFP , and Foxp3 DTR-GFP/+ mice were injected with B16.F10 melanoma tumor cells intradermally (ID) on day 0. Tumor growth was measured with digital calipers every 3 days. Mice were removed from study when tumor growth reached a diameter of 2 cm in any direction or when necrosis was observed, and survival plots were generated (four experiments, n = 9-18). (F and G) Foxp3 DTR-GFP/DTR-GFP and Foxp3 DTR-GFP/+ mice were treated with 100 mg diphtheria toxin intraperitoneally (i. 
, and Nrp1
Cre-YFP/DTR-GFP mice and cultured with effector T cells and APCs for 72 hr in a classical microsuppression assay. Tregs were pooled from three mice with five to six mice per group per experiment. Proliferation was measured and percent suppression was calculated as described in the STAR Methods. Data represent three to five (A-C), four (D-G), or three (H) independent experiments. Error bars represent the mean ± SEM. Student's unpaired t test (B and H), two-way ANOVA (E and G), and KaplanMeier tests (E and G) were used. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figures S1 and S2.
heterozygous mice relative to Nrp1 +/+ T regs in Foxp3
Cre-YFP/Cre-YFP mice as expected ( Figures S2D and S2E ). However, elevated pAkt and, to a lesser extent, reduced ICOS, was also observed in
Cre-YFP/DTR-GFP heterozygous mice.
Taken together, these data suggest that Nrp1 -/-T regs have a negative impact on the suppressive function of intratumoral Nrp1 +/+ T regs .
Fragile and WT T regs Have a Reciprocal Impact on Their Transcriptome
We next used transcriptomic analysis of Nrp1 +/+ and Nrp1 -/-T regs from Foxp3
Cre-YFP/DTR-GFP mice to evaluate the cell intrinsic and extrinsic impact of Nrp1 loss ( Figure S3 ). Significant alterations in the T reg transcriptome were observed between Nrp1 +/+ and Nrp1 -/-T regs . Principal component analysis (PCA) based on differentially expressed genes clearly separated T eff and T regs based on both location and genotype. Interestingly, intratumoral Nrp1
Cre-YFP/DTR-GFP mice were similar to each other and yet distinct from their genotypically identical counterparts from control A similar impact was observed when T reg signature genes were assessed wherein it became evident that all four populations were distinct and yet bore a transcriptional relationship (Figure S4C) . These data suggest that Nrp1
Cre-YFP/DTR-GFP mice impact each other's transcriptome in a reciprocal manner.
Pathway analysis highlighted a potential role for IFNg/interleukin (IL)-12-related transcriptional programs. Of particular interest was an increase in Ifng and its targets in Nrp1
ures 2B, 2C, and S4D), implicating a role for the IFNg pathway in modulating T reg function in the tumor microenvironment. While previous reports have suggested that a small subset of T regs produce IFNg during inflammation (Duhen et al., 2012; Koenecke et al., 2012; Pandiyan and Zhu, 2015) , the expression of IFNg by T regs in tumors and its impact on their suppressive function remains unclear. Using flow cytometry, we found that there was increased expression of IFNg by Nrp1
Cre-YFP/DTR-GFP mice ( Figures 3A and 3B ). Interestingly, an increased per-
Cre-YFP/DTR-GFP mice also expressed IFNg. Interferon-g receptor 1 (IFNgR) expression showed an elevated trend in Nrp1
Cre-YFP/Cre-YFP mice and both Nrp1 -/-and Nrp1
Cre-YFP/DTR-GFP heterozygous mice ( Figure 3B ). In addition, several type 1 helper T cell markers were upregulated in Nrp1 -/-T regs , such as Tbet, Cxcr3, and Eomes (Figures S5A-
Cre-YFP/DTR-GFP mice and pSTAT4 in all Nrp1 -/-T regs (Figures S5G and S5H) . In order to determine whether modulation of IFNg and IFNgR expression also occurred following blockade of the Nrp1:Sema4a axis, we treated B16 tumor-bearing mice with 
Cre-YFP/Cre-YFP , and Nrp1
Cre-YFP/DTR-GFP mice on D12, cDNA, and libraries were generated using the Clontech SmartER Ultra-Low and Illumina Nextera XT Library Prep kits. Samples were normalized to 2 nM and sequenced on a NextSeq500. (A) Differentially expressed genes are determined by the genes that have q value of 0.2 between any two of the four T reg groups in the TIL. PCA was computed using the ''prcomp()'' R functions using the normalized voom data restricted to the same differentially expressed genes as shown in figure. (B and C) Significant genes were cross-referenced with those that were annotated to ''plasma membrane'' or ''extracellular part'' in the Cellular Component Gene Ontology. Sema4aIg (Delgoffe et al., 2013) . Indeed, Sema4aIg treatment decreased tumor size and led to an unstable T reg phenotype as assessed by increased IFNg production and higher IFNgR expression ( Figures 3C-3E) . Surprisingly, we found that the majority of the IFNg + cells in the tumor infiltrating lymphocytes (TILs) of
Cre-YFP/DTR-GFP were T regs ( Figure 4A ) and that the total percentage of IFNg + cells in TIL was small in the absence of T reg -restricted Nrp1 deletion (Figure 4B) , raising the possibility that IFNg production may be a dominant feature of T reg fragility and thus could be affecting surrounding cells in the tumor microenvironment including Nrp1 +/+ T regs .
While our data show that T regs were the predominant source
Cre-YFP/DTR-GFP mice, we could not rule out the possibility that IFNg production by fragile T regs was initially triggered, or potentiated by, the altered tumor microenvironment. Indeed, tumor size is greatly reduced and lymphocyte infiltration increased in Nrp1
Cre-YFP/DTR-GFP mice (Figures 1E and S1A) . In order to address this possibility, we blocked the anti-tumor immune response and prevented tumor shrinkage by depleting CD8 + T cells (using anti-CD8) in B16
tumor-bearing mice and assessed T reg phenotype and function. We found that CD8 + T cell depletion had no effect on the
Cre-YFP/DTR-GFP mice. Indeed, Nrp1 -/-T regs exhibited increased IFNg and Tbet protein expression along with reduced suppressive capacity in an in vitro suppression assay, suggest- (E) Lymphocytes were isolated from ndLN and TIL and stained for IFNgR (n = 5). Data represent three to four independent experiments. Student's unpaired t test was used. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figure S5 .
ing that T reg fragility due to Nrp1 loss is primarily due to a cell intrinsic mechanism rather than an extrinsic environmental effect due to increased CD8 + T cell infiltration, the ensuing anti-tumor response, and tumor size ( Figures 4C-4E and S5I ). However, a role for CD8 + T cell-derived IFNg in promoting T reg fragility in this system cannot be ruled out. Although cell-intrinsic processes downstream of Nrp1 loss appeared to drive T reg fragility, it is still possible that cell-extrinsic, environmental factors facilitated intratumoral T reg fragility. Further analysis of our RNA sequencing (RNA-seq) data highlighted enhanced expression of Hif1a (hypoxia-inducible factor 1 alpha) in Nrp1 -/-compared to Nrp1 +/+ intratumoral T regs (Figure 4F) . Indeed, the percentage of Hif1a + Nrp1 -/-intratumoral T regs and Hif1a protein expression within those T regs was higher than their Nrp1 +/+ counterparts ( Figure 4G ). Interestingly, Hif1a
has been shown to be upregulated by Akt signaling, which in turn led to increased IFN-g production by T regs (Dang et al., 2011; Lee et al., 2015) . As Hif1a is upregulated in hypoxic conditions, we wondered whether hypoxia was capable of inducing T reg fragility, analogous to the environment in which intratumoral T regs reside. Remarkably, LN-derived T regs from a naive mouse showed increased IFN-g and Tbet expression and an elevated trend in Hif1a expression while retaining Foxp3 expression after being cultured for 3 days in hypoxic versus normoxic conditions ( Figures 4H, S5J , and S5K). These data suggest that the hypoxia:Hif1a axis may prime T regs to become functionally fragile in the tumor microenvironment. 
Foxp3
Cre-YFP mice (T regs that lack the IFNg receptor) with Nrp1
Cre-YFP mice prior to assessing their regulatory activity in a microsuppression assay ( Figure 5A ). All cell populations were also cultured alone under the same conditions as controls, and as anticipated, T reg populations cultured alone exhibited the expected suppressive capacity ( Figure 1H T regs that were co-cultured with tumor-derived Nrp1 -/-T regs lost their ability to suppress effector T cells, in contrast to ndLN-derived T regs ( Figure 5B , right side columns). Loss of suppressive activity did not require cell-cell contact, but was dependent on IFNgR expression (Figures 5B-5D ). In order to confirm that IFNg was the sole cytokine responsible for Nrp1 +/+ T reg fragility following co-culture with Nrp1 -/-T regs , we co-cultured Nrp1 +/+ and Nrp1 -/-T regs in the presence of different concentrations of anti-IFNg for 72 hr and then assessed the suppressive 
Cre-YFP/Cre-YFP mice were injected with B16.F10 melanoma tumor cells ID on day 0 and sacrificed on day 12. Lymphocytes were isolated from ndLN and TIL and stained for Hif1a (n = 10).
(H) T regs were isolated from LN of Foxp3 Cre-YFP/Cre-YFP mice, stimulated for 3 days in hypoxia or normoxia, and stained (n = 4-6). Data represent two to five independent experiments. Student's unpaired t test was used. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figure S5 .
capacity of the purified Nrp1 +/+ T regs in the absence of anti-IFNg.
IFNg neutralization prevented the loss of tumor-derived Nrp1
T reg suppression in a dose-dependent manner ( Figures 5E and  S6A ). The increased sensitivity of tumor-versus ndLN-derived Nrp1 +/+ T regs to Nrp1 -/-T regs appeared to correlate with IFNgR expression ( Figure S6B ).
While previous studies have suggested that IL-12 can impact T reg suppression and induce IFNg expression (Koch et al., 2012; Zhao et al., 2012) , whether IFNg has a direct effect on T regs and if so what impact that might have in their function remains obscure. In order to determine whether IFNg was sufficient to limit suppressive capacity, we treated Nrp1 +/+ T regs from ndLN and TIL with IFNg for 72 hr plus IL-2 in stimulating conditions prior to assessing their functional capacity in a microsuppression assay in the absence of cytokine. IFNg substantially limited the suppressive capacity of TIL-derived, and to a lesser extent ndLN-derived, Nrp1
+/+ T regs in a dose-dependent manner (Figure 5F ). This effect was lost if Ifngr1 -/-T regs were used (Figure S6C) . Pre-treatment with IFNg also induced IFNg expression by WT T regs but not Ifngr1 -/-T regs ( Figure S6D , and data not shown). Given that IFNg limits the function of murine T regs , we asked whether IFNg could also impact human T regs and whether this was enhanced by the human tumor microenvironment. Indeed, intratumoral human T regs showed an increased sensitivity to IFNg in comparison to PBL T regs when cultured with the cytokine 72 hr prior to assessment of their suppressive capacity in the absence of cytokine ( Figure 5G ). Furthermore, intratumoral NRP1 + T regs appeared to be less sensitive to the effects of IFNg than NRP1 -T regs . Taken together, these data suggest that IFNg can undermine the function of murine and human T regs in vitro.
We next sought to determine if Nrp1 -/-T reg -derived IFNg from could drive Nrp1 +/+ T reg fragility in vivo. To address this, we used
-/-mice that lack T regs and succumb to a scurfy-like 
(D) Quantification from (C). (E) T regs were isolated from ndLN and TIL of Foxp3
Cre-YFP/Cre-YFP mice, co-cultured with Nrp1 -/-T regs and IL-2 in the presence or absence of anti-IFNg, re-sorted, and used in a microsuppression assay in the absence of cytokine (n = 6).
(F) T regs were isolated from ndLN and TIL of Foxp3
Cre-YFP/Cre-YFP mice, treated with IL-2 and IFNg for 72 hr, re-sorted, and used in a microsuppression assay in the absence of cytokine (n = 6). (G) T regs were isolated from HNSCC PBL and TIL, cultured with IL-2 ± IFNg for 3 days, then used in a microsuppression assay in the absence of cytokine (n = 2-14). Data represent three to five experiments. Error bars represent the mean ± SEM. Student's unpaired t test (A-D) and two-way ANOVA (E-G) were used. *p < 0.05, **p < 0.01, ****p < 0.0001. See also Figure S6 .
phenotype if T regs are not adoptively transferred within 48 hr of birth (Workman et al., 2011) . T regs of a single genotype or a 50:50 mixture of two different T reg genotypes were adoptively transferred into 2-day-old Foxp3 -/-mice. At 4 weeks of age, mice were injected with B16 melanoma and tumor growth assessed over time ( Figure 6A ). Mice were monitored after T reg injection and removed from study prior to B16 injection if any signs of autoimmunity were observed (Workman et al., 2011 
). Strikingly, tumor growth was completely restored with either combination ( Figures  6E-6H) , revealing a critical role for IFNg produced by fragile Nrp1 -/-T regs in mediating Nrp1 +/+ T reg dysfunction and thereby facilitating anti-tumor immunity and limiting tumor growth.
IFN-g-Induced T reg Fragility Is Required for Effective PD1-Targeted Immunotherapy
While our previous data suggested a prominent role for IFN-g in driving T reg fragility, the importance for this observation in the broader context of an immunotherapeutic response is unknown. We sought to address this question using mice that lack IFN-gR on T regs (Ifngr1 L/L Foxp3 Cre-YFP ) ( Figures S7A and S7B ).
Ifngr1
L/L Foxp3 Cre-YFP Cre-YFP mice following anti-PD1 treatment (Figure 7B) . Taken together, these data suggest that IFN-g-induced T reg fragility is required for an effective response to PD1-targeted immunotherapy.
DISCUSSION
In summary, our data highlight seven key observations. First, a high proportion of human T regs expressed NRP1 in two tumor types: melanoma and HNSCC. It is also noteworthy that PBL T regs from these cancer patients also possessed a clear population of NRP1 + T regs in contrast to healthy donor PBL T regs , which exhibited little to no NRP1 expression. Interestingly, the percentage of intratumoral NRP1 + T regs appeared to correlate with poor disease prognosis. Second, B16 tumors were rapidly cleared in mice harboring a 50:50 mixture of Nrp1-deficient and WT T regs due to increased functional fragility and loss of suppressive activity of both T reg populations without loss of Foxp3 expression. This was the result of Nrp1-deficient T reg fragility rather than the generation of Foxp3 -ex-T regs . Third, T reg fragility had a reciprocal impact on the transcriptomes of Nrp1-deficient and WT T regs , highlighting the previously unappreciated fact that T regs can impact other T reg populations directly as well as many other cell types. Fourth, the induction of IFNg pathway genes was a dominant feature of T reg fragility in tumors. Intratumoral T regs were more susceptible to this functionally fragile phenotype due to the hypoxic tumor microenvironment, which led to increased Hif1a expression and IFNg production (Lee et al., 2015) . While it is possible that IFNg derived from other sources could lead to T reg fragility, we have shown that hypoxia promoted IFNg production and T reg fragility. Fifth, IFNg, exogenously-provided (human or mouse) or intratumoral Nrp1
-/-T reg -derived Koch et al., 2012; Zhao et al., 2012) , while others show that IFNg can limit T reg expansion (Deligne et al., 2015; Olalekan et al., 2015; St Rose et al., 2013; Visperas et al., 2014) . However, the direct effect of IFNg on T reg function in vivo had surprisingly not been appreciated. While some studies have shown that IFNg + T regs can maintain suppressive function, this seems to be largely disease-specific and has not been carefully assessed in the context of the tumor microenvironment (Oldenhove et al., 2009; Zhao et al., 2011) . It is possible that the tumor microenvironment plays a critical role in driving IFNg-mediated T reg fragility, as suggested by the role of Hif1a in this process. In addition, while we anticipate that IL-12 may be playing a role in this process given that we see increased pSTAT4 expression, we have shown that IFNg is capable of driving T reg fragility both in vitro and in vivo in tumor-derived T regs exposed to a hypoxic environment. (Figures 5E, 5F , and 6), suggesting that IL-12 may not be essential. Sixth, intratumoral T reg fragility was mediated by IFNg derived from Nrp1 -/-T regs that acted on WT intratumoral T regs , thereby leading to their fragility and loss of suppressive activity. This was supported by the fact that inclusion of WT T regs that could not respond to IFNg or Nrp1 -/-T regs that could not produce IFNg restored T reg function, blocked anti-tumor immunity, and promoted tumor growth. While these data suggest that Nrp1 -/-T reg -derived IFNg is required, we do not yet know if it is sufficient. These observations were consistent with a model in which fragile Nrp1 -/-T regs produce large amounts of IFNg in the tumor microenvironment that directly promotes the fragility of intratumoral WT T regs without loss of Foxp3 expression. Importantly, this occurred without any detectable peripheral T reg fragility and without impacting their maintenance of peripheral tolerance, suggesting that this was a proximally and locally driven event, likely induced by inflammation. While we only observed this in the context of the tumor microenvironment, it is possible that T reg fragility could indeed occur in other inflammatory settings where exposure to IFNg is increased. We would argue that the mechanism of IFNg-induced T reg fragility is mediated directly between Nrp1 -/-and WT T regs as either loss of IFNg or IFNgR expression, respectively, impacts fragility. While it is possible that IFNg derived from other cell populations, such as CD8 + T cells or NK cells, or the ensuing anti-tumor response and altered tumor microenvironment contributed to T reg fragility, it is noteworthy that the dominant IFNg-producing cell type was Nrp1 -/-T regs and CD8 + T cell depletion did not impact the enhanced IFNg production and loss of suppressive activity observed. Seventh, IFNgR expression on intratumoral T regs was required for an effective response to PD1 blockade
Cre-YFP mice were completely resistant to anti-PD1 immunotherapy. Whereas WT T regs showed a significant increase in IFNg expression after PD1 blockade, Ifngr1
-/-T regs showed no increase in IFNg, suggesting that IFNg-driven T reg fragility may need to be induced for an effective immunotherapeutic response. A previous study had suggested that the absence of Nrp1 leads to reduced influx of T regs into certain tumor types (Vegfa +/+ or Vegfa -/-fibrosarcomas and Ret melanoma models) (Hansen et al., 2012) . However, we did not observe any defect in the migration of Nrp1-deficient T regs even in the competitive environment of B16 tumors in heterozygous Nrp1 L/L Foxp3 Cre-YFP/DTR-GFP female mice. These discrepancies could be due to the different tumor models analyzed. Alternatively, their study primarily utilized Nrp1 L/L CD4 Cre mice in which Nrp1 would be removed in all T cells, which could have many direct and indirect effects on intratumoral T regs (Hansen et al., 2012) . Indeed, we and others have shown that Nrp1 is expressed on a number of cell types, especially in the tumor (Jackson et al., 2014 ) (data not shown). Whether T reg fragility is a feature of certain diseases and the extent to which this can be prevented or utilized therapeutically remains largely unknown and highly controversial (Rubtsov et al., 2010; Sakaguchi et al., 2013; Zhou et al., 2009a Zhou et al., , 2009b . We speculate that the IFNg pathway may drive T reg fragility in certain inflammatory environments. The loss of Nrp1 not only results in T reg fragility but also results in substantial IFNg expression, which in turn induces fragility in other T regs regardless of their Nrp1 expression in a feed-forward manner; a process we refer to as ''infectious fragility.'' As IFNg production is a hallmark of a productive T cell-mediated immune response, our observations also raise the possibility that IFNg-induced T reg fragility may be a physiologically important regulatory mechanism to locally limit T reg function and promote a productive immune response. Given the profound consequences of T reg -derived IFNg production, our data emphasize the importance of the Nrp1 pathway in limiting T reg fragility in the tumor microenvironment but also highlight that this pathway can be overcome when sufficient IFNg is induced. Indeed, our data show that the IFNg response induced by PD1 blockade appears to be sufficient to drive intratumoral T reg fragility despite expression of Nrp1. However, loss of IFNgR expression on T regs renders mice completely resistant to anti-PD1 immunotherapy. This raises the provocative possibility that an essential component of effective immunotherapy is to induce sufficient IFNg in the tumor microenvironment to drive T reg fragility. However, the impact of T reg fragility and IFNg expression by intratumoral T regs on tumor growth and responsiveness to immunotherapy in murine and human tumors needs to be investigated further.
As a high frequency of intratumoral T regs in cancer patients is largely considered a negative prognostic factor (Facciabene et al., 2012; Ichihara et al., 2003; Knol et al., 2011) , identifying approaches to selectively target intratumoral T regs while maintaining peripheral tolerance is critical. Although expression of NRP1 in peripheral, tissue-resident T regs remains unclear, our findings highlight the surprisingly extensive and variable expression of NRP1 on human intratumoral T regs (Battaglia et al., 2008 (Battaglia et al., , 2009 Chaudhary et al., 2014; Milpied et al., 2009) . Importantly, given that our mouse model experiments suggest that NRP1 may not need to be targeted in all human intratumoral T regs to derive a therapeutic effect, it is possible that targeting NRP1 + intratumoral T regs with an NRP1 monoclonal antibody (mAb) may be therapeutic. As we show that the impact of the IFNg pathway on human T regs is conserved, it is possible that by blocking NRP1 on T regs , one could induce functional fragility in surrounding T regs to further enhance the therapeutic effect and overall outcome. Our identification of IFNg as the critical mediator of T reg fragility, whether driven by manipulation of the Nrp1 pathway in T regs or PD1 blockade highlights the potential importance of this mechanism in promoting anti-tumor immunity and provides a pathway to develop immunotherapeutic approaches that could lead to tumor reduction while maintaining peripheral tolerance.
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Detailed methods are provided in the online version of this paper and include the following: Piechnik, A., Dmoszynska, A., Omiotek, M., Mlak, R., Kowal, M., Stilgenbauer, S., Bullinger, L., and Giannopoulos, K. (2013 -/-male pups within 2 days of birth (Workman et al., 2011) . When a 50:50 mixture of T regs was injected the total was maintained at 1 3 10 6 cells. Mice were monitored for the autoimmune phenotype 'scurfy' (scaly skin, eye inflammation, runted phenotype, and lack of mobility) (Workman et al., 2011) . Any mice exhibiting any autoimmune or inflammatory symptoms prior to B16 injection, even if mild, were removed from further study. Mice were injected with 1.25 3 10 5 B16.F10 cells at 4 weeks of age and tumor growth was monitored every 3 days.
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Gene Expression Profiling by RNaseq and Bioinformatics Analyses
Tregs (5x10 3 ) were either single (n = 3) or double sorted (n = 2) and cDNAs were prepared using the SMARTerâ UltraÔ Low Input RNA size is defined as AUC (area under receiver operating curve) -0.5 which provides a normalized ranksum statistic that is comparable across genesets of different sizes. The plot is restricted to the top 10 pathways (based on their Nrp1 +/+ versus Nrp1 -/-significance) from the ''canonical'' mSigDB geneset. We additionally restricted this analysis to genesets and pathways that were deemed relevant to intercellular signaling (defined at least half of the genes in the geneset having an extracellular or membrane annotation). Cre-YFP mice were treated with 20 mg/mL mytomycin C (Sigma) at 37 C for 30min, washed five times with PBS, and then used as antigen presenting cells (APCs). Responder cells (4x10 3 ), APCs (8x10 3 ), and different concentrations of T regs (1:2-1:16 T reg :T eff ratio, 500-2000 T regs ) were activated with 2 mg/ml anti-CD3 (Biolegend) in a 96-well round bottom plate with 100ul RPMI for 3 days (Turnis et al., 2016) . Suppression was calculated as previously described (McMurchy and Levings, 2012) . Briefly, cells were acquired by BD Fortessa, and the division index of responder cells was analyzed using FlowJo based on the division of CellTrace Violet. Suppression was then calculated with the formula % Suppression = (1-DIT reg /DICtrl) x 100% (DIT reg stands for the division index of responder cells with Tregs, and DICtrl stands for the division index of responder cells activated without T regs ). Human microsuppression assays were performed similarly to mouse assays with the following changes: 0.5 mg/ml anti-CD3 is used for activation, and cells are cultured in assay conditions (200uL) for 4 days. For co-culture assays, sorted T reg populations were cultured together in a 96 well round-bottom plate or in a 96 well transwell plate (Millipore) for 72 hr prior to being resorted and used in a suppression assay. Cells were treated with 100ng/mL PMA (Sigma), 500ng/mL Ionomycin (Sigma) and 1000IU hIL-2 (Prometheus) for co-culture. For some experiments, sorted T regs were cultured in the presence of 0.3-20ng/mL anti-IFNg (BioXcell) or 0-200ng/mL IFNg (Biolegend) to the microsuppression assay.
In Vitro Assays
For the hypoxia assays, T regs were stimulated with PMA/Ionomycin and IL-2 for 3 days in normoxic (5% CO 2 and 20% O 2 ) or hypoxic (5.5% CO 2 and 1.5% O 2 ) conditions at 37 C. Cells were then stained in the same condition in the absence of cytokine.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistics were performed using Prism v6.07. Student's t tests were used in Figures 1B, 1H , 3B-3E, 4B-4D, 4F, 4G, 5B, 5D, 7B, 7C, S1A, S1B, S2E, S2F, S5, S6B-S6D, and S7C. ANOVA was used in Figures 1C, 1E , 1G, 5E-5G, 6, and 7A. Kaplan Meier was used in Figures 1C, 1E , 1F, and 7A. n represents the number of mice used in the experiment, with the number of individual experiments listed in the legend. Graphs show individual samples. Samples are shown with the mean with or without error bars showing the SEM. Significance was defined as p = 0.05.
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